Treatment of a first episode of psychotic illness with quetiapine: An analysis of 2 year outcomes

Schizophrenia Research

Volumn 81, Issue 1, 2006, Pages 29-39

  Kopala, Lili C ^a   Good, Kimberley P ^b   Milliken, Heather ^b   Buiteman, Christine ^b   Woodley, Hazel ^b   Rui, Qing ^b   Whitehorn, David ^b   Love, Leslie ^c   Balshaw, Robert ^c   Kiss, Ivan ^b   Honer, William G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c Syreon Corporation   (Canada)

Author keywords

Antipsychotics; Cognition; Metabolism; Movement disorder; Psychosis; Quetiapine; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; LOXAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; ATTENTION; CANADA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; ERROR; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPOTENSION; LABORATORY TEST; MALE; METABOLISM; MOOD DISORDER; MOTOR DYSFUNCTION; NEUROPSYCHOLOGICAL TEST; PARKINSONISM; PERSEVERATION; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SEDATION; SENSORIMOTOR FUNCTION; SIDE EFFECT; SOCIAL STATUS; STANDARDIZATION; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VELOCITY; VERBAL BEHAVIOR; VERBAL MEMORY; VISION; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PSYCHOMOTOR DISORDERS; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 29144476592     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.09.009     Document Type: Article

References (42)

1. D. Addington, J. Addington, and B. Schissel A depression rating scale for schizophrenics Schizophr. Res. 3 1990 247 251
2. J. Addington, C. Mansley, and D. Addington Weight gain in first-episode psychosis Can. J. Psychiatry 48 2003 272 275
3. D. Allison, J. Mentore, and M. Heo Antipsychotic-induced weight gain: a comprehensive research synthesis Am. J. Psychiatry 156 1999 1686 1696
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders fourth edition 1994 American Psychiatric Association Washington, DC
5. A. Benton A Test of Three Dimentional Constructural Praxis: Manual 1974 University of Iowa: Neurosensory Center Publication
6. A. Benton, and K. Hamsher Multilingual Aphasia Examination 1989 AJA Associates Iowa City, Iowa
7. R. Bilder, R. Goldman, and J. Volavka Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder Am. J. Psychiatry 159 2002 1018 1028
8. B. Cornblatt, M. Lenzenweger, and L. Erlenmeyer-Kimling The continuous Performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients Psychiatry Res. 29 1989 65 85
9. G. Chouinard, A. Ross-Chouinard, and L. Annable The extrapyramidal symptom rating scale Can. J. Neurol. Sci. 7 1980 233
10. M. Freedman, S. Black, and P. Ebert Orbitofrontal function, object alternation, and perseveration Cereb. Cortex 8 1998 18 27
11. K. Good, I. Kiss, and C. Buiteman Improvement in cognitive functioning in patients with first episode psychosis during treatment with quetiapine: an interim analysis Br. J. Psychiatry 181 2002 45 49
12. D. Gothelf, B. Falk, and P. Singer Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine Am. J. Psychiatry 159 2002 1055 1057
13. M. Green What are the functional consequences of neurocognitive deficits in schizophrenia Am. J. Psychiatry 153 1996 321 330
14. W. Guy ECDEU Assessment Manual for Psychopharmacology (revised) 1976 National Institute of Mental Health Rockville, MD
15. P. Harvey, M. Green, and S. McGurk Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study Psychopharmacology (Berl.) 169 2003 404 411
16. R. Heaton, G. Chelune, and J. Talley Wisconsin Card Sorting Test Manual 1993 Psychological Assessment Resources Odessa, FL
17. H. Jin, J. Meyer, and D. Jeste Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases Ann. Clin. Psychiatry 14 2002 59 64
18. H. Jin, J.M. Meyer, and D.V. Jeste Atypical antipsychotics and glucose dysregulation: a systematic review Schizophr. Res. 71 2-3 2004 195 212 Dec 1
19. M. Jones-Gotman, and B. Milner Design fluency: the invention of nonsense drawings after focal cortical lesions Neuropsychologia 15 1977 653 674
20. S. Kay The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr. Bull. 13 1987 262 275
21. L. Kopala, K. Good, and D. Fredrikson Risperidone in first-episode schizophrenia: improvement in symptoms and pre-existing extrapyramidal signs Int. J. Psychiatry Clin. Pract. 2 1998 19 25
22. J. Lieberman, D. Jody, and S. Giesler Time course and biological correlates of treatment response in first-episode schizophrenia Arch. Gen. Psychiatry 50 1993 369 376
23. J.A. Lieberman, G. Tollefson, M. Tohen, A.I. Green, R.E. Gur, R. Kahn, J. McEvoy, D. Perkins, T. Sharma, R. Zipursky, H. Wei, R.M. Hamer HGDH Study Group Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol Am. J. Psychiatry 160 8 2003 1396 1404 Aug
24. M. Lezak Neuropsychological Assessment Third edn. 1995 Oxford University Press New York
25. T. Manschreck, L. Kopala, and W. Honer Neurological comorbidity and features in schizophrenia J.M. Meyer H.A. Nasrallah Medical Illness and Schizophrenia 2003 American Psychiatric Press Washington, DC 185 214
26. S.R. Marder, J.M. Davis, and G. Chouinard The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials J. Clin. Psychiatry 58 1997 538 546
27. J.M. Meyer A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year J. Clin. Psychiatry 63 2002 425 433
28. J.M. Meyer Cardiovascular illness and hyperlipidemia in patients in schizophrenia J.M. Meyer H. Nasrallah Medical Illness and Schizophrenia 2003 American Psychiatric Press Washington, DC 59 89
29. J. Meyer, and C. Koro The effects of antipsychotic therapy on serum lipids: a comprehensive review Schizophr. Res. 70 2004 1 17
30. M.J. Minzenberg, J.H. Poole, C. Benton, and S. Vinogradov Association of anticholinergic load with impairment of complex attention and memory in schizophrenia Am. J. Psychiatry 161 1 2004 116 124 Jan
31. H. Nasrallah A review of the effect of atypical antipsychotics on weight Psychoneuroendocrinology 28 2003 83 96
32. H.A. Nasrallah, S.D. Targum, and R. Tandon Defining and measuring clinical effectiveness in the treatment of schizophrenia Psychiatr. Serv. 56 3 2005 273 282
33. S. Purdon, A. Malla, and A. Labelle Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol J. Psychiatry Neurosci. 26 2001 137 149
34. G. Ratzoni, D. Gothelf, and A. Brand-Gothelf Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study J. Am. Acad. Child Adolesc. Psych. 41 2003 337 343
35. R. Reitan Validity of the trail making test as an indicator of organic brain damage Percept. Mot. Skills 8 1958 271 276
36. A. Rey L'examen clinique en psychologie 1964 Presses Universitaires de France Paris
37. K. Sax, S. Strakowski, and P. Keck Attentional improvement following quetiapine fumarate treatment in schizophrenia Schizophr. Res. 33 1998 151 155
38. N. Schooler, J. Rabinowitz, and M. Davidson Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial Am. J. Psychiatry 162 5 2005 947 953
39. H.E. Spohn, and M.E. Strauss Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia J. Abnorm. Psychol. 98 4 1989 367 380 Nov
40. L. Voruganti, P. Slomka, and P. Zabel Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging Neuropsychopharmacology 25 2001 642 650
41. D. Velligan, J. Newcomer, and J. Pultz Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr. Res. 53 2002 239 248
42. P. Weiden, R. Aquila, and M. Emanuel Long-term considerations after switching antipsychotics J. Clin. Psychiatry 59 1998 36 49